Almedalen 2017 logos website

 

Wisby Strands Veranda & Taverna

 

After Work Almedalen

Onsdag 5 juli 2017 kl. 17:00 – 19:00

Wisby Strands Veranda

Opticom, Adxto & Mimerex
arrangerar även i år ett gemensamt mingel för våra kunder.
Vi bjuder på rosé, tilltugg samt ett lättsamt samkväm med kollegor i branschen.
Vi kommer vid tillfället att informera om våra verksamheter.

Vi hoppas att du vill komma och ser fram emot att träffa dig!

Varmt välkommen önskar
Carl Michael Bergman, Helena Östregård, Pontus Torstensson och kollegor

Tyvärr har vi ett begränsat antal platser, så anmäl dig gärna så snart som möjligt: Anmälan
Om du får förhinder, meddela oss gärna via: almedalen@opticom.se

Vill du veta mer om vad vi på Opticom, Adxto och Mimerex arbetar med? Kontakta oss gärna eller besök våra hemsidor:

Carl Michael Bergman, VD, Opticom: carl.michael@opticom.se  Opticom Group Opticom International Research

Helena Östregård, VD, Adxto helena.ostregard@adxto.com Adxto

Pontus Torstensson, VD, Mimerex pontus.torstensson@mimerex.com Mimerex

 

Download PDF

Health Logos June 2017

We at Opticom are happy and grateful for the valuable partnerships and inspiring journey we have been part of the last 30 years!

We thank all our clients for trusting Opticom with important projects, and we also thank all of our co-workers and business partners for their hard work and commitment to Opticom.

Our roots stem from research and analysis, which has provided our clients with true customer understanding. This understanding has served as the foundation for decisions that aim at creating substantial value for our customers in Health, Forest Products and Industrial Goods. Numerous client testimonials show that research pays off.

Over the years, we have added Consulting to our offering, helping our clients to use real-world insights to improve business decision making. Research and Consulting are the two disciplines that we have built our success upon: it has been our privilege to serve an incredible list of globally leading companies.

In 2014, we added Communication as the third leg of our business, and thus today we at Opticom Group feel honoured to offer global research, consulting and communication.

Today we are very much looking forward to the next 30 years and beyond. We can assure you that we will continue to be passionate about understanding your key challenges and in finding solutions that deliver true value.

Download PDF

Eye for pharma pic

Opticom took the opportunity to hear and discuss What’s cooking in Pharma, at the annual Eye for Pharma’s Barcelona Conference 2017.

Buzz words such as patient empowerment, digital services, multi-stakeholder collaboration, and customer engagement confirm that the industry is clearly widening its “customer focus” to include a stronger patient centricity and closer stakeholder collaboration as well as a broader definition of offering value through innovative services.

Opticom will continue to help health companies succeed in their healthcare ecosystem. Do contact us if you would like to talk, brainstorm, and plan your next steps towards improved value propositions!

Some interesting quotes caught at Eye for Pharma Barcelona 2017:

“Technology forces us forward: pharma on its own will cause an evolution, by partnering with external partners, we will create a revolution.” (Panel discussion)

On Patient value: “We need to get patients to be proud of us – Pharma – proud of what we have achieved. We should do a better job to convince them.” (Panel discussion)

Bottom line: regardless of the value offered: “Never surprise us (patients) with any side effect!” (Ian Talmage, Senior Advisor, Bayer)

“Pharma’s role: Helping people to get better at getting better.” (Panel discussion)

“What is the most advanced pharma company when it comes to digitalization? Not just one company, but we can see indications that they are often the smaller, midsize companies, from the Nordics or Belgium.” (Dr. Frank Kumli, Executive Director, Life Sciences, EY)

Download PDF

The Swedish health care system is mediocre at using innovative medicines compared to other countries in Europe. This is a result that surprises Europeans – but not Swedes. This according to a new survey Opticom has carried on behalf of LIF – the research-based pharmaceutical companies.

A summary article from LIF’s seminar during Almedalen is presented in the report “Vården i Almedalen 2013″. This report is an editorial magazine where the communication agency Gullers Group make sure that what is being said in Almedalen does not just stay on the island of Gotland. Since 2010, the report summarises and analyses the most important health care issues during the week – and how health care stakeholders would like to resolve them. The report is organized according to the themes that dominated the week and shows current trends and developments in Swedish health care.

To read the article (in Swedish), click here.

To access the full report “Vården i Almedalen 2013″, click here.

For more information about the study conducted on behalf of LIF, please contact project manager Marijn van der Sluijs at +46 8 50 30 90 00 or marijn [at] opticom [dot] se.

Download PDF

During a seminar in Almedalen on the 5th of July, Opticom presented a report on why the use of innovative drugs differs between comparable countries in Europe. The report was prepared on behalf of LIF, the trade association for the research-based pharmaceutical industry in Sweden. To provide LIF with a deeper understanding of why the use of innovative drugs differs among comparable countries, Opticom conducted interviews with approximately 200 Key Opinion Leaders and representatives for government authorities and other national organisations, in four core therapeutic areas in six European countries: Sweden, Denmark, the Netherlands, Germany, the United Kingdom and France.

LIF-presentation-Almedalen

For the four selected therapeutic areas, IMS Health provided LIF and Opticom with data how innovative medicines are prescribed in the various countries, which in turn enabled a ranking of countries. These rankings then formed the basis for discussion with the respondents. For the therapeutic areas that the survey focused on – Alzheimer’s, anticoagulants, diabetes, and oncology Sweden landed in positions 10 to 17, when the use of innovative drugs compared to 27 European countries.

The fact that Sweden is relatively low in these international comparisons is something that surprises respondents outside Sweden. The image of Sweden as an innovative country with high welfare is fairly widespread in Europe leads to the expectation that Sweden would be a country that should take more of a leading position.

To access a summary of the results, please choose your language below:
English or Swedish

To access the full report (in Swedish) – click here.

For more information about this report, please contact project manager Marijn van der Sluijs at +46 8 50 30 90 00 or marijn [at] opticom [dot] se.

Download PDF